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Abstract
Recent studies have shown that a single asymptomatic dose exposure to the nerve
agent sarin in mice leads to long term cardiac dysfunction. This study looked at
immediate and delayed treatment therapies post sarin exposure on cardiac function.
Heart function and structure were studied using electrocardiography (EKG) and
histological/immunochemical techniques (staining with hematoxylin/eosin and brain
natriuretic peptide, BNP). Male C57BL/6J mice were injected with sarin (0.4LD50)
followed immediately with atropine/2PAMCL (standard nerve agent treatment) or at 9
wks with β adrenergic agonist/antagonist. Measurements were made ~ 3 months post
sarin. Mice given atropine/2PAMCL showed significantly higher cardiomyocyte size
and BNP levels than controls (p = 0.001). EKGs showed T-wave anomalies. These
results are indicators of cardiac insult. The second treatment groups received
isoproterenol or propranolol (β agonist and antagonist, respectively, sc infusion for 2
wks) after onset of cardiac remodeling. Isoproterenol increased heart weight (p = 0.0018)
and myocyte size and caused inverted T-waves. Propranolol treated mice showed only Twave depression with no change in heart size. Results suggest 1) standard
atropine/2PAMCL treatment does not prevent sarin-induced cardiac dysfunction and in
fact may cause pathologies and 2) β agonist stimulation exacerbates the cardiac response
to sarin suggesting possible interactions between sarin and stress exposure.
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IMMEDIATE AND DELAYED DRUG THERAPY EFFECTS ON LOW DOSE SARIN
EXPOSED MICE MYOCARDIAL PERFORMANCE

I. Introduction
Historical Use and Future Concerns of Sarin
Sarin is a highly lethal neurological toxin which was first created in 1938. It is a
colorless and odorless liquid which rapidly evaporates into the gaseous state. The
Germans weaponized and stockpiled sarin during WWII, along with other chemical
agents, but never employed them. Since WWII, there have been multiple confirmed and
suspected uses of chemical warfare agents (CWA) in conflicts around the world; Yemen
Civil War (1963-1967), Soviet’s in Afghanistan (1979-1989), Iran-Iraq War (1980-1988),
Iraq against the Kurds (1988), and Libya against Chad (1987) (Salem, et al. 2008). In all
of these military actions nerve agents were among those chemical agents suspected of
being employed, additionally the perpetrators of the chemical agent use were all national
governmental organizations. In the mid 90’s chemical agent attacks no-longer became
the sole domain of nation states. In 1994 and 1995 a cult group known as Aum
Shinrikyo, employed sarin against Japanese government and civilian targets leading to
wide spread civilian casualties (Committee on Gulf War and Health: Updated Literature
Review of Sarin 2004, Ferguson 2009). In 1998 Bin Laden stated it was a religious duty
to acquire Weapons of Mass Destruction (WMD) in defense of Muslims. In 2003,
Shaykh nasir bin Hamid al-Fahd, a young cleric wrote a religious paper entitled “A
1

Treatise on the Legal Status of Using Weapons of Mass Destruction”, further defending
the “right” of terrorists to acquire and use WMDs (Ferguson 2009). As a result,
increasing efforts have been undertaken to be able to better protect and respond to both
military and civilian causalities from a nerve agent attack. However, treatment and
detection capabilities are still based on symptomatic dose levels, which, leaves gaps in
our ability to properly identify and treat casualties to low level asymptomatic exposure to
nerve agent.
Sarin and nerve agents have again become a topic for research in the last two
decades following the unintentional exposure of U.S. Soldiers in 1991 to low levels of
nerve agent following the destruction of the Khamisiyah munitions site in Iraq (see
Figure 1).

Figure 1. Plume Models for the Demolition of Bunkers at Khamisiyah, 12 March 1991
(Persian Gulf War Illnesses Task Force 1997)
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According to the Committee on Gulf War and Health estimates, nearly 90,000 Soldiers
may have been exposed to sarin and/or cyclosarin following the demolitions at the
Khamisiyah site (Committee on Gulf War and Health: Updated Literature Review of
Sarin 2004). Due to this potential exposure to sarin and other nerve agents, they were
implicated as possible etiological agents in those suffering from Gulf War Illness (GWI).
Theses chemical agents were therefore recommended by a Presidential Advisory
Committee to be the subject of extensive investigation by agencies that treat those
veterans (Couzin 2004, McDonough and Romano 2008)
Problem Statement
Past research and medical information focused on understanding symptomatic
large dose exposure affects from nerve agents, little to no information is available
concerning asymptomatic low dose and late-onset effects from nerve agent exposure.
With the possibility of personnel exposures at these low levels occurring near the attack
site, a better understanding is needed on possible health effects of low dose exposure
levels. Additional understanding of these possible health effects could also lead to
changes in current mission oriented protective posture (MOPP) guidance for military
personnel. This is due to the fact that current guidance only considers doses which
present clinical signs of nerve agent exposure as relevant. Also, current detectors are
unable to detect agents below symptomatic levels. Further understanding of late-onset
symptoms and affects on personnel could also lead to changes in long term treatment of
nerve agent exposure victims.
Recent studies by Morris and Horenziak focused on the long term cardio-toxic
effects following a single asymptomatic dose (Morris, Key and Farah 2007, Horenziak
3

2010). Initial findings by Morris et al. linked autonomic changes with the heart in mice,
after exposure to low doses of nerve agent, which showed increases in heart rate
variability, (Morris, et al. 2007). In the recent study by Horenziak, data indicates delayed
onset of morphology and reduced cardiac function of mice exposed to low doses of the
nerve agent, sarin. It was also shown that, even with normal cardiac function during
basal conditions, cardiac function showed reduced levels of performance when stressed
(Horenziak 2010).
A Review on the Chemistry and Toxicology of Sarin
Sarin, chemical name isopropyl methylphosphonoflouridate (military designation
– GB), belongs to a class of chemical compounds known as organophosphates.
Organophosphates are chemical toxins that inhibit acetyl cholinesterase (AChE) and are
widely used as commercial pesticides and CWA. Sarin’s toxic effect is the result of its
ability to phosphorylate the serine hydroxyl residue in the active pocket of AChE,
forming either a phosphoric or phosphonic acid ester which is extremely stable. This
reaction irreversibly deactivates or “inhibits” the enzyme (Abou-Donia 2003). In sarin’s
case the irreversible binding or “aging” is a process which can occur that permanently
binds the sarin to AChE thus preventing reactivation of the enzyme (CDC 2007). As
AChE becomes inhibited acetylcholine (ACh), a cholinergic neurotransmitter, builds up
at receptor sites causing overstimulation. Overstimulation occurs at the central and
peripheral cholinergic sites in smooth muscles, skeletal muscles, most exocrine glands,
the central nervous system (CNS), and the cardiac system (e.g. central and ganglionic
afferents), (Horenziak 2010).
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Stimulation of muscarinic receptors at the smooth muscle level causes miosis,
bronchioconstriction, vasodialation, increased peristalsis, and reduced heart rate at
smooth muscle level. At exocrine glands, it causes secretions in the lung, nasal, oral, and
sweat glands. Clinical effects due to nicotinic receptor overstimulation at skeletal muscles
are fasciculation, twitching, flaccid paralysis and stimulation of autonomic ganglia
leading to tachycardia and hypertension. The CNS has both muscarinic and nicotinic
receptors and overstimulation leads to seizures and can cause death; whereas, a mild
exposure leads to variety of symptoms which include forgetfulness, bad dreams,
insomnia, and the inability to concentrate (USAMRID 2007, Horenziak 2010).
Sarin affects the cardiovascular system in a complex manner; effects are due to
actions on both ganglion and postganglionic consequences of accumulated ACh on the
heart and blood vessels. The overall acute effect on the heart depends on the relative
prevalence of sympathetic or parasympathetic effects. Cholinergic effects from ACh
suppress vagal tone resulting in a decreased refractory period and conduction time at
sinoatrial (SA) and atrioventricular (AV) nodes. An excess of Ach also affects the
muscarinic ACh M2 receptors in heart leading to negative chronotropic and ionotropic
effects. Thus, ACh creates contradicting excitatory effects on parasympathetic
ganglionic cells in the face of the inhibitory effects of the sympathetic ganglia. The
build-up of ACh elicits similar excitatory, followed by inhibitory, effects at the medullary
vasomotor and cardiac centers. In severe ACh accumulation, hypoxia resulting from
bronco-constriction also affects the cardiovascular system by reinforcing sympathetic
tone, while ACh induced epinephrine release from adrenals leads to increased heart rate.
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As a result, sarin induces bradycardia, tachycardia, and arrhythmias in the heart that can
lead to spontaneous cardiac failure (Taylor 2001, Horenziak 2010).
To counteract nerve agent exposure, the medical and military community uses a
two or three drug combination to treat affected persons. Each drug has a specific affect
on the patient which when used in combination can counter the acute effects of nerve
agent exposure. The drugs are atropine, an anticholinergic compound, pralidoxime
chloride (2PAMCL), an oxime, and diazepam, an anticonvulsant. Atropine/2PAMCL or
MARK I will be used throughout the paper to denote the use of the two drug antidote
sequence atropine plus parlidoxime chloride. Atropine (the primary drug treatment for
nerve agent exposure) is used to block excess Ach at peripheral muscarinic sites which
results in a decrease in secretions and an increase in heart rate. 2PAMCL is used to
reactivate affected Ache and acts by binding to the nerve agent that is attached to the
Ache and then breaks the nerve agent-enzyme bond, restoring the Ache to full
functionality. This reaction is only possible if the nerve agent has not “aged”, if aging
has occurred the Ache cannot be restored to functionality and Ache levels can only be
increased by new production in the body, typically at the rate of about 1% a day.
Diazepam is only used in cases of extreme nerve agent exposure to prevent brain injury
caused by convulsions and seizures (USAMRID 2007).
Research Objectives/Hypothesis
The research objectives for this study are two-fold. First, is to evaluate the
effectiveness of immediate treatment after exposure with atropine/2PAMCL to prevent
cardiac remodeling. Second, is to study the effects of β receptor agonists and antagonists
on cardiac performance and morphology, with no prior treatment, after sarin induced
6

cardiac remodeling has occurred. These studies will help to create a better understanding
of the long term effects expected to manifest following a low-dose sarin exposure with
the use of the MARKI antidote kit in troops or the general population.
Additional Specific Aims are:


Determine the time course of cardio toxic actions of sarin in mice. Using an
asymptomatic dose of sarin, follow the EHCO and ECG changes up to 8 weeks
post exposure in mice with and without nerve agent antidote treatment
(atropine/2-PAMCL). This will help to test the hypothesis that prompt treatment
with nerve agent antidote will prevent long cardiac remodeling in exposure
victims.



Determine the effect of sarin combined with a hypertrophic stimulus,
isoproterenol. The hypothesis is that there will be an exacerbation of the cardio
toxic effects of sarin.



Determine the effects of the blockade of β-adrenergic function and inhibition of
central sympathetic outflow on the cardio toxic effects of sarin. The hypothesis is
that treatment with a β-blocker will help reverse the cardiac remodeling induced
by an acute low dose exposure to sarin.

Experimental Design
Male mice (C57BL6 strain) were injected on two consecutive days by WSU
personnel and broken into six groups of 10 mice each. The groups were; control,
control+atropine/2PAMCL, 0.4LD50 sarin, 0.4LD50 sarin+atropine/2PAMCL, groups five
and six were given 0.4LD50 of sarin and then further broken down into three groups
which were given saline, isoproterenol, and propranolol respectively.
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Table 1. Study Groups

Sarin
Recovery Week 3
Injection
Control
x
x
x,y
Sarin
x
x
x,y
Control+Atropine/2PAMCL
x
x
Sarin+Atropine/2PAMCL
x
x
Sarin+Saline
x
x
Sarin+Isoproterenol
x
x
Sarin+Propranpolol
x
x

Week 7
x,y,z
x,y,z
x,y,z
x,y,z
x,y
x,y
x,y

Week 9 Week 11

x,y
x,y
x,y

x,y,z
x,y,z
x,y,z

x - Body Weight Measurements Taken
y - ECG Mesurements Taken
z - Sacrifice

Each group was studied using both in vivo (ECG analysis, echocardiography
(ECHO)) and histological techniques (brain natriuretic peptide (BNP), hematoxylin and
eosin (H&E), and Masson Trichrome) to determine if there were any changes in cardiac
function or any cardiac remodeling occurring. At various points post exposure a shortacting β-1 specific agonist (dobutamine) was used to study cardiac performance during
elevated cardiac output conditions. Various ECHO and ECG measurements were taken
to measure left ventricular structure and cardiac performance before and after a
dobutamine stress test. At the end of each study period the mice were sacrificed and
relevant tissues and organs were taken for follow-on histological analysis.
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II. Literature Review
Introduction
Recent studies by Morris Lab at Wright State University (WSU) have examined
cardiac morphology and other changes to the hearts of mice after acute asymptomatic
doses of sarin (Morris, Key and Farah 2007, Horenziak 2010). This study looked at
effects of atropine/2PAMCL antidote treatment and various β adrenergic drug treatments
on mice, after asymptomatic dose exposure levels to sarin.
Animal Considerations
Mice, unlike humans have higher levels of carboxyl esterase which has been
shown too rapidly and degrade sarin. These elevated levels of carboxyl esterase change
the normal dose response curve in mice compared to that of humans (Li, et al. 2005,
Jokanovic, et al. 1996). This natural protective nature of carboxyl esterase requires that
the mice be dosed on consecutive days. The first dose is used to consume the
endogenous carboxyl esterase in the mice which then allows the second dose to follow a
dose response curve that more accurately reflects that seen in humans. To verify that the
desired level of acetyl cholinesterase inhibition has been achieved in the mice, serum
cholinesterase assays are performed by Dr. Lucot following a protocol used by Sidell et
al (Sidell and Borak 1992).
Choice of Anesthesia and Expected Effects
Conducting non-invasive observation techniques to measure cardiac performance
requires taking into account affects on the mice due to the techniques used and the data
that is to be collected. There have been well documented differences between conscious
and unconscious mice in ECHO and ECG which are used to measure cardiac
9

performance. Studies which used ECHOs have shown a decrease in heart rate variability,
fractional shorting, and ejection fraction in unconscious mice (Tan, et al. 2003, Stein, et
al. 2005, Roth, et al. 2002). Additionally, ECG recordings have shown increases in QT
and PR intervals and decreases in heart rate (Chavesa, et al. 2003).
Despite the potential drawbacks with using sedatives, it has been shown that they
help to reduce stress in the mice, which, should lead to significantly reduced variabilities
seen in ECHOs when compared to conscious mice; this is due to differences in stress
created in the mice from the restraints or the handling training the mice received (Tan, et
al. 2003). Other research by, Kramer et al. has shown that using restraints on mice leads
to increases in body temperature, blood pressure, heart rate, plasma levels, and variable
responses to pharmaceutical treatments (Kramer, et al. 2001). Additionally, issues
related to high heart rates from stress and transducer placement due to small movements
in conscious mice have led to failures in obtaining quality ECHO recordings (Roth, et al.
2002, Tan, et al. 2003). Issues associated with taking ECG recordings in conscious mice
include being able to only take short time interval readings and the development of
movement artifacts in the recordings. To prevent issues with lead placement on the mice
the ECG probes are typically implanted in the mice or require restraints, both of which
lead to increases in time and cost verses using anesthesia (Chavesa, et al. 2003).
Isoflurane (ISF) is the agent of choice for animal research and has been shown in
multiple research papers to have the least affects on the heart compared to other
anesthesia during ECHO and ECG analysis (Tan, et al. 2003, Stein, et al. 2005, Roth, et
al. 2002, Chavesa, et al. 2003). Another benefit of ISF is that it has a more rapid onset
time and provides more reproducible results than other which make it preferable for short
10

lived experiments (Stein, et al. 2005). Due to inherent advantages of ISF over conscious
mice and its extensive successful use at WSU’s Live Animal Research (LAR) lab in
previous sarin related research it was chosen for use in this experiment in order to
maintain procedural consistency. All mice were treated with ISF in the same manner to
conduct ECHO and ECG analysis, as such, there is expected to be little to no effect on
the procedural outcomes.
Body Temperature Regulation Concerns
Research has shown that mice are unable to regulate their body temperature when
they are sedated; this can lead to significant fluctuations in heart rate and cardiac function
(Hartley, et al. 1995, Hartley, et al. 2002). Changes in performance can occur with
changes as little as 40C (Swoap, et al. 2004). To minimize issues with changes in body
temperature, the room was temperature controlled at (220C ± 10C); additionally, thermal
pads (Brain Tree Scientific, Delta Phase Isothermal Pad for 37oC (model # 39DP)) were
used to maintain body temperature at 320C ± 20C during the in vivo monitoring process.
Dobutamine Stress Testing
Cardiac function can change depending upon whether the subject’s heart is
experiencing normal (unstressed) or increased (stressed) cardiac output conditions. It is
therefore important to test cardiac function in both states to evaluate overall cardiac
function. Dobutamine is a drug that is commonly used in cardiac stress testing to study
cardiac function in a stressed state. It acts on the β1 adrenergic site and is a preferred
drug for this type of testing due to its strong but short lived actions on the heart
(Anderson, et al. 2008, Daly, et al. 1997, Mertes, et al. 1993, Shaheen, et al. 1998). The
duration of the tachycardia lasts for approximately 25 minutes and creates an oxygen
11

supply-demand mismatch in the heart by increasing myocardial oxygen demand
(Weissman, et al. 1996, Wiesmann, et al. 2001). Due to the preferential nature of
dobutamine to bind to the β1-adrenoreceptors, using it to conduct the stress test can
provide information on the overall function of the receptor cascade by using ECG and
ECHO analysis to observe the changes (Anderson, et al 2008, Weissman, et al. 1996).
An important consideration in using dobutamine for the stress testing is that in low doses
it has not been shown to have any long lasting effects on the heart. However, if it is
administered continuously over a period of time (seven days) it has been shown to
increase fibrosis and lead to hypertrophy in the heart (Anderson, et al. 2008). The mice
were given dobutamine during weeks; 3, 7, 9, and 11 as part of the stress test in doses of
1mg/kg body weight (approximately 30µg/mouse). The low dose levels and time interval
in-between injections should prevent any long-term damage due to the dobutamine
stimulation of the hearts.
Noninvasive In Vivo Measurements
Echocardiograms
Echocardiography is a well known and widely used noninvasive procedure to
measure and determine aspects of overall cardiac function in humans and animals. The
most widely used imaging techniques are the 2D, M-mode, and Doppler. Using these
modes it is possible to measure heart rate, wall thickness, left ventricular area, and the
myocardial performance index (Horenziak 2010). While ECHO was performed during
each stage of the experiment, equipment data recording failures prevented proper analysis
of the data and thus precluded its use in this study.
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Electrocardiograms (ECG)
Electrocardiography has been widely used in murine research for over 70 years to
look at electrical impulses of the (Hartley, et al. 2002, Wehrens, et al. 2000). The
characteristic readout of ECGs is due to the successive electric impulse propagation
throughout the heart. The beginning of the heart beat occurs at the sinus node then
rapidly moves through the atria, which is indicated by the P wave. The following PR
interval represents the movement of the impulse to the AV node. The ventricular
contraction is shown via the QRS complex that immediately follows the PR interval.
Atria repolarization occurs during ventricular contraction, but does not show due to the
height and intensity of the QRS complex. The following ST segment represents
ventricular relaxation and is then followed by the T-wave which represents ventricular
repolarization. The initial impulse then dissipates, which is shown by the return to the
iso-electric line (see Figure 2), (Ramos 2003, Geiter 2007, Horenziak 2010).

T-wave merged
with QRS
T-wave end
T-wave peak

Figure 2. Typical Human ECG

Figure 3. Typical Mouse ECG Illustrating the
Difference in the T-wave when Compared to the
Human ECG

(This image is licensed for unrestricted redistribution
(Atkielski 2007)).
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The ECG of mice has one distinct difference from that of humans. In mice the Twave is merged with the end of the QRS complex which results in noticeable lack of a ST
segment (see Figure 3), (Wehrens, et al. 2000, Mitchell, et al. 1998, London 2001). The
T wave in mice begins above the iso-electric line and then falls below it and is followed
by a gradual return back to the iso-electric line (Mitchell, et al. 1998, Horenziak 2010,
Wehrens, et al. 2000, London 2001). The T-wave is typically the first place on an ECG
that changes from its normal pattern when issues occur in cardiac performance. Cardiac
insults can result in T-wave inversions, ST depression, elongation of the QT interval, or
even a lack of a T-wave (Geiter 2006). By analyzing changes to and anomalies on the
ECG, any number of dysfunctions in the cardiovascular system can be observed and
therefore treated.
In Vitro/Histological Markers
Utility of BNP Measurements
In the recent study by conducted by Horenziak, brain natriuretic peptide (BNP)
levels were significantly increased in sarin treated mice. This peptide was first observed
in pig brains (hence the name) but is only expressed in the ventricles of humans and mice
(Brain natriuretic peptide 2010). The presence of increased BNP levels has been shown
to occur after the heart undergoes a serious insult and hypertrophy has occurred (He, et
al. 2001). Brain natriuretic peptide is created and stored in ventricular cells and increases
in response to cardiac stress and are a sign of heart failure, hypertrophy, or any number of
stresses to the heart (Goetze, et al. 2009, Yasuno, et al. 2009). The different natriuretic
peptides have also been shown to have protective effects against hypertrophy in vitro
when released from the cells (London 2006). Brain natriuretic peptide exerts its
14

natriuretic, diuretic, and vasorelaxant effects through activation of its common receptor
Natriuretic Peptide Receptor A (NPRA) (Kawakami, et al. 2010, London 2006). Another
important aspect of BNP is that it is expressed in fetal ventricles but is not present in
significant amounts in adult mice ventricles (Scott, et al. 2009). These characteristics of
BNP mean that it can serve as an excellent marker of cardiac insult to the murine heart, as
such its presence or lack thereof should provide an indication of whether
atropine/2PAMCL treatment, post sarin exposure can protect the heart.
Hematoxylin and Eosin (H&E) Staining
Hematoxylin and eosin staining is a commonly used technique in preparation of
histology slides. Hematoxylin and eosin stains nuclei purple to blue and the rest of the
cell pink to red (Eroschenko 2008). As such, the H&E stain provides important
information about the nuclei and muscle fiber arrangement and cell size when heart
sections are examined under a microscope (Horenziak 2010). For this study the H&E
stained slides were used to obtain an estimate of average cell size by taking a ratio of
nuclei to cell area.
Drug Therapies
Atropine+2PAMCL
Atropine plus 2PAMCL is the standard treatment for nerve agent poisoning by
both the military and emergency medical personnel. It is administered via the Mark-I kit
which has 2mg of Atropine and 600mg of 2PAMCL (Meridian Medical Technologies,
Inc. 2003). After exposure to a nerve agent the Mark I kit can be administered up to three
times prior to treatment by medical personnel (USAMRID 2007). The number of Kits
used depends upon the severity of the poisoning; current protocol is not to use the kits if
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the person is asymptomatic (USAMRID 2007, New York State Department of Health
Bureau of Emergency Medical Services 2003).
Atropine acts as a competitive receptor antagonist, blocking the effects of ACh at
the muscarinic sites preventing it from lowering the heart rate to dangerous levels after
nerve agent exposure (USAMRID 2007, Brown and Taylor 2001). The second half of
the Mark I kit, 2PAMCL, acts as a cholinesterase reactivator by rehydrolyzing the
enzyme allowing it to resume hydroxylation of the ACh, thus deactivating it as
neurotransmitter (Parkinson 2003, Hoffman and Taylor, Neurotransmission: The
Autonomic and Somatic Motor Nervous Systems 2001). The intent of this research is to
determine whether a small dose of the atropine/2PAMCL nerve agent treatment kit can
have a protective effect on the cardiac tissue post exposure to sarin.
Propranolol
Propranolol is a Class II antiarrhythmic drug which acts as a β-adrenergic receptor
blockade (Ramos, et al. 2003). Major benefits of propranolol are reduced heart rate,
decrease in myocardial oxygen demand, and reduction in arterial blood pressure (Kerins,
et al. 2001). Recent studies have shown that the antihypertrophic effects of propranolol
are independent of its β-adrenergic blockading ability. These effects in rats were found
when doses of 40 and 80 mg/kg per day were given over a 17 day period (Marano, et al.
2002).
Isoproterenol
Isoproterenol is a non selective β-adrenergic agonist which also has a low affinity
for α-adrenergic receptors. As a catecholamine, effects of isoproterenol on the heart lead
to increased heart rate, increased myocardial oxygen demand, and possible electrolyte
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alterations (Ramos, et al. 2003, Hoffman 2001). Cardiac researchers have been using
isoproterenol for around fifty years as a means to induce hypertrophy in small animals
(Anderson, et al. 2008). By treating the sarin treated mice with isoproterenol and with a
β-blocker (propranolol) it is hoped that insight into mechanisms by which sarin acts on
heart can be found.
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III. Methodology
Animal Experimental Protocol
Sixty-two C57BL/6J male mice were used in two studies (41 in the atropine study
and 21in the β adrenergic drug therapy study). They were individually housed at 22oC on
a 12:12 light-dark cycle at the WSU LAR. Forty-two mice were treated with sarin nerve
agent on two consecutive days. The other 20 mice were treated with saline and acted as
the control mice. In-vivo cardiac performance measurements were taken along with
weight during weeks three, seven, nine, and 11 post sarin exposure.
Compared to humans, mice have a higher level of blood cholinesterase which
interacts with and consumes nerve agent, preventing the agent from acting on the nervous
system and organs. To ensure proper dose response, mice were treated with sarin twice;
the first dose metabolically consumes the cholinesterase in the blood followed by a
second injection 24hrs later which exerted the inhibitory response that was studied.
Twenty-four hours after the final injection the blood cholinesterase levels were measured
using a standard assay developed at WSU (Horenziak 2010). Following the last dose of
sarin, 10 mice from the control group and 10 mice from the sarin group were given an
atropine/2PAMCL treatment of 10 and 25 mg/kg respectively.
Two separate studies were conducted; the first (referred to as the Atropine Study)
looked at antidote treatment effects following low dose exposure to sarin, which
consisted of control, control+atropine/2PAMCL, 0.4LD50 sarin, and 0.4LD50
sarin+atropine/2PAMCL groups. The control and sarin groups from the first study had 8
and 7 mice surgically implanted with ECG telemetry probes from Data Science
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International (model TA-F10) to record continuous ECG data after the week three in vivo
analysis. The probes were set to record for 15 minutes every hour for 24hrs.
The second (referred to as the β adrenergic drug therapy study) looked at various
drug treatments on sarin exposed mice, which consisted of 0.4LD50 sarin+saline, 0.4LD50
sarin+isoproterenol, and 0.4LD50 sarin+propranolol groups. These mice were evaluated
at week nine and then micro-osmotic pumps (model 1007D from Alzet®) were implanted
to administer doses of saline (20mg/kg/day), isoproterenol (30mg/kg/day), and
propranolol(20mg/kg/day) over a two week period. At the end of the two weeks (week
11) the mice were evaluated in vivo and then sacrificed.
Tissue Collection and Histology Sectioning
In the seventh week the atropine study mice were sacrificed and in week 11 the β
adrenergic drug therapy study mice were sacrificed via decapitation and tissue samples
were collected and preserved. After the mice were decapitated the heart was collected,
weighed, and then placed into a phosphate buffered saline (PBS) solution. Each heart
had its apex removed and the heart was placed in a 4% paraformaldehyde (PFA) solution
and stored at 4oC for 48 hours. Following soaking for 48 hours in the PFA the tissues
were removed and fixed in 20% sucrose, 4% PFA solution. They hearts were then stored
for another 24 hours at 4oC and then transferred to a -80oC freezer where they were stored
until they were sent to AML Laboratories for heart sectioning. Each mouse was
sectioned into five slides with two heart sections per slide. One of the slides from each
mouse was stained with Hematoxylin and Eosin (H&E) by AML. Additionally, AML
stained one slide from each group with masson’s trichrome which allows for the study of
collagen fibers.
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Hematoxylin and Eosin Analysis Methods
Hematoxylin and eosin staining is a common staining technique used to highlight
nuclei from cell tissue. In this experiment H&E stained slides were analyzed to compare
overall cell size. All H&E staining was conducted by the AML personnel at the same
time as the heart sectioning. They were used to conduct cell size analysis via nucleus to
pixel area ratio. The H&E stained slides were analyzed using a slightly modified version
of a protocol that was used by Horenziak. The slides were viewed under a Leica
Microsystems® DMR microscope at 20X Magnification (see Figure 4).

Figure 4. H&E Stained Slide at 20X Magnification

Pictures of the whole heart section were taken with an Optronics® QuantFIRE®
XI/MacroFIRE® 2.3A camera attached to the microscope. Corresponding software was
used to manipulate the image to obtain the greatest contrast from the stain. Once the
settings for the image were set they were not changed. It was found during research
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conducted by Horenziak that taking the images in a gray scale allowed for better contrast
and analysis later on.
The first step was to take a picture of the white background in an area near the
heart sections, followed by a black background taken with the light source turned off.
These images were then used to correct the background later during analysis. Each heart
had three photos taken of the left ventricle at random locations that did not overlap.
To conduct the image analysis a Molecular Devices’® software package called
Metamorph® (version 7.6) was used. The Background and Shading Correction function
was used to correct uneven intensity on all images due to staining irregularities. This
required taking both the white and black background images along with the image being
analyzed and running it through the Background and Shading Correction function. The
new “corrected” image became the image that was used to conduct all analysis. Using a
control mouse the Color/Intensity threshold selection tool was used to determine the
threshold levels that allowed distinction between the background and cell tissue which
where, 0-252 (see Figure 5).
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Figure 6. Threshold and IMA Selection of Nuclei

Figure 5. Threshold Selection of Total Cell Area

Next a range of threshold values and Area/Shape filter parameters from the Integrated
Morphometry Analysis (IMA) tool kit were determined to allow for the counting of
nuclei (see Figure 6). The Area filter was set to only select highlighted areas consisting
of areas from 50-800 pixels total. The Shape filter was also set to select highlighted areas
which conformed to a circular shape match of .250 to 1.00. These values were based on
measurements of nuclei in a control mouse. The threshold values for the nuclei varied
between slides due to inconsistencies in staining intensity and nuclei locations. This
required adjustment of the threshold values mouse by mouse to ensure proper selection of
nuclei. Finally, the total number of objects was exported to Excel™ using the Object tab
in IMA tool kit. Next, the total area of the cell tissue was determined using the values
stated above and then exported to Excel™ in the same manner as the nuclei data. The
average cell size was computed as the number of pixels per nuclei. The values were
averaged and compared using statistical techniques described later.

22

Brain Natriuretic Peptide Methods
Brain Natriuretic Peptide Staining Methods
Brain natriuretic peptides are commonly released after a cardiac insult and its
presence is a good indicator of heart damage. Unstained slides from AML with fixed
heart tissue were first de-paraffined by soaking the slides in xylene for five minutes
twice. This was followed by a rehydration sequence which took the slides from 100%
ethyl alcohol down to 70% over a 24 minute period. The slides were then rinsed in
0.01M phosphate buffered saline solution (PBS), twice. Then the slides were placed in a
0.15% hydrogen peroxide solution for 15 minutes and washed in PBS (standard washing
was conducted three times). Following this the slides were blocked using normal goat
serum for one hour prior to the addition of the primary antibody solution. The primary
antibody solution consisted of rabbit/anti-rat antibodies and was obtained from Bachem
AG® and was diluted to a ratio of 1/500, antibody to blocking solution. The slides were
maintained at room temperature for one hour and transferred to a 4oC storage container
overnight. The following morning the slides were washed in PBS and then the second
antibody was placed on the slide tissue for 35 minutes. The second antibody was a
goat/anti-rabbit solution obtained from Vectastaintm and was diluted to a ration of 1/500,
antibody to blocking solution. The slides were then washed in PBS and the reagent A+B
solution from the Elite® Vectastaintm ABC stain kit (rabbit IgG) was added to the tissue
for one hour. The slides were then washed using a nickel buffer solution three times and
then stained for ten minutes. The staining solution was a 3-3’-Diaminobenzidine
tetrahydrochloride (DAB) tablet crushed and dissolved in the nickel buffer solution. The
slides were then washed in PBS and dehydrated in ethyl alcohol of increasing
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concentrations from 70% to 100%. Finally they were cover slipped and allowed to dry
before being analyzed using a microscope.
Brain Natriuretic Peptide Analysis Methods
The BNP stained slides were analyzed using a slightly modified version of a
protocol that was used by Horenziak. The slides were viewed under the same microscope
and pictures taken with the same camera as the H&E tissue. The same software was used
to manipulate the image to obtain the greatest contrast from the stain, but unlike the H&E
these images were taken in color. Again, once the settings for the image and light
settings were set they were not changed. Background images in light and dark settings
were taken in the same manner as the H&E slides. Each heart section was completely
photographed, which required approximately four to six screen shots each.
The image correction process was the same as the H&E tissues and like them the
“corrected” image was then analyzed. To conduct the image analysis a Molecular
Devices’® software package called Metamorph® (version 7.6) was used. The
Background and Shading Correction function was used to correct all images to correct
uneven intensity of the images due to staining irregularities. This required taking both
the white and black background images along with the image being analyzed and running
it through the Background and Shading Correction function. The new “corrected” image
became the image that was used to conduct all analysis.
Once all the images for each heart section were corrected a selection tool was
used to trace sections from each image which when combined with the other sections
selected, outlined the whole heart section. The selection of all the cell tissue and BNP
stained tissue was accomplished using the Threshold Analysis Tool. The threshold values
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used to select the BNP for each slide were slightly different due to variations of the stain
concentrations for each slide. The threshold values for the tissue were conducted in the
same manner as that for the BNP stained tissue but were set to include all heart tissue.
Using the regional statistics tab, the total number of pixels in the traced region for
both BNP and total cell area were calculated for each picture. This information was
recorded and then combined with all picture sections in Excel™ to determine the total
BNP and tissue pixel areas for the complete heart section. A ratio of BNP to total cell
area was then calculated to normalize the data for statistical comparison.
Electrocardiography Methods
Data Collection Procedure
Electrocardiography is an excellent non-invasive method to observe cardiac
performance. It was conducted on every mouse that underwent ECHOs during weeks
three, seven, nine, and 10. The mice were first weighed using a Denver Instruments®
XP-500 electronic scale in the surgical suite. After the mice were weighed they were
placed in an anesthesia chamber and anesthetized using a forced flow 2% ISF in pure
oxygen mixture, the anesthesia was administered via a Surgivet Anesco® Isotec 4™
anesthesia machine (see Figure 7). Once the mice were knocked out, they were moved
to observation table and placed on the isothermal pad and subjected to a constant flow of
1% ISF for the duration of the examination. The front two legs of the mice were spread
and taped to the pad to help immobilize the mice. To achieve proper contact for the two
ECG leads the mice had their chest hair removed with Nair™ and cleaned with an
isopropyl alcohol pad (see Figure 8).
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Figure 7. Mouse in Anesthesia Chamber

Figure 8. Application of Hair Remover to Mouse

Electrocardiography data recordings were taken, before and after, dobutamine was
administered to the mice (via subcutaneous injection see Figure 9), and between the pre
and post dobutamine ECHO imaging.

Figure 9. Injection of Dobutamine to Study Mouse

Recordings pre and post dobutamine injection lasted approximately three to four minutes
each. The electrodes were attached using Schwartz micro-serrefine clips. The first lead
was placed below the neck line in the dorsal thoracic region near the front right leg; the
second lead was placed in the lower left abdominal area of the mouse (see Figure 10).
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Figure 10. Placement of ECG Leads on Mouse

The advantage of using the isothermal pad was that it did not interfere with the ECG
recording process like the electric heating pads used in the past. After the leads were
placed the probe was laid on the DSI PhysioTel® receiver to allow maximum reception.
The ECG readings were recorded using DSI’s Dataquest A.R.T.™ (version 4.0)
software. Prior to recording, the probes calibration information from the manufacturer
was inputted into the software and set to record in ECG mode and the sampling
frequency was set to 5000 kilohertz. The ECG recordings were taken for approximately
six to seven minutes. After the first two minutes the mice were injected with dobutamine
(1mg/kg) to create a stressed state in the heart. The ECG readouts were monitored to
observe the onset of the dobutamine induced stress and once achieved the recordings
continued for a few more minutes.
Electrocardiography Analysis Method
All ECG recordings were analyzed using DSI’s Ponemah™ software program
(version 4.90), and a modified version of the protocol developed by Horenziak. The
A.R.T. files were uploaded and converted into the software program. Prior to beginning
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data analysis, under the Ponemah™ Platform tab, data recording parameters were set to
record, all derived data and an analysis template blank were opened. Additionally, the
scale was set to -0.5mV and 1.0mV to allow for the best view of the ECG recording.
Once the parameters was set up, the ECG recording analysis attributes values had
to be adjusted because the predetermined QT interval for murine analysis was to long (it
was lowered from 100 to 70 milliseconds). After changing the QT interval the entire
ECG tracing was analyzed. Due to the limits of the software and the variability in the
recording values not all P and T-waves were marked. In order to mark the missing P and
T-waves the software’s template analysis toolkit was used by taking a representative
wave and adding the missing markers and reanalyzing the ECG tracing for any wave
sections that were an 80% match (see Figures 11 and 12 for defined points on the ECG
readout).

R-wave peak

R-wave peak

P-wave start

P-wave end

Q-wave peak

S-wave end
T-wave end
T-wave peak
S-wave peak

Figure 11. Significant Points on a Mouse ECG

P-wave start

P-wave end

Q-wave peak

S-wave end
T-wave end
T-wave peak

S-wave peak

Figure 12. Example of Marker Placement by
Ponemah™ Software

The wave analysis using templates was done until the entire tracing was marked properly.
The subjective nature of placing the missing markers required that standardization of
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wave placements be adhered to. The placement of the P-wave was defined as the small
inverted u shaped wave prior to the QRS complex. Due to differences between T-waves
in humans and mice the T-wave markings had to be further defined. The peak of the Twave was defined as the maximum deflection from the iso-electric line after the end of
the S-wave (see Figure 11). However, in stressed conditions and some pre stressed drug
treated mice the peak of the T-wave was defined as the last saddle point prior to the
tracing returning to the iso-electric line due to an inversion of the T-wave. The end of the
T-wave was defined in all cases as the point where the tracing returned to the iso-electric
line. If the T-wave had not returned to the iso-electric line prior the start of the P-wave
(thus merging with the P-wave) the end of T-wave was defined as the point just prior to
the start of the P-wave (see Figure 13).
Once the tracing was marked it was reviewed to find a uniform 30 second interval
pre and post dobutamine. These 30 second intervals were then reviewed beat-by-beat to
remove any beats that could not be marked properly (caused mainly by movement or
breathing (see Figure 14). These marks were removed and any beats that could be
marked and were missed were marked at this time. After this the Derived data was then
converted and saved as an Excel™ file.
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P-wave start

T-wave end

Figure 13. Example of ST Segment Merging with
the P wave

Figure 14. Example of ECG Degradation Due to
Respiration

Once the data was converted to Excel™ format, several corrections to the data had to be
made; adjustments to the RR interval were corrected to compensate for removed beats;
QT interval, ST segment, and T interval were corrected for heart rate. Ponemah™
defines the RR interval as the interval from one marked R-wave to the next R-wave; as
such if one beat (and thus the R-wave) was deleted due to a breath (or other anomaly) the
corresponding RR interval would be twice the normal value. To correct the RR interval
were beats had been removed the RR value was divided by the number of beats removed
to correct it. After the RR interval was corrected a corrected QT interval was then
calculated (relabeled as QTc) using the derived QT interval and a method which
normalizes the interval to 100 beats per minute (Mitchell, et al. 1998). This is required
due to high resting heart rates of mice.
(1)
To analyze abnormalities in ST segments and T intervals (from T peak to T end)
novel methods had to be created due to the lack of a true ST segment in mice, unlike that
of humans. It has been noted that in mice there is an early peaking in the T-wave (which
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is also merged with the end of the S-wave), (Horenziak 2010). To overcome these issues
Van Acker et al. developed a method by which depressions and elevations of the ST
segment (which is defined as the distance from end of S to the T peak) can be measured
(van Acker, et al. 1996, Horenziak 2010). The T interval is defined as the difference
between, T peak and T end, accordingly the following formula were used to determine
STc and Tc.
(2)
(3)

Figure 15. Parameters Used in and Derived from the Equations (1, 2, and 3)

Unlike in the study by Horenziak, the T peak was used in place of the QTAN due to large
numbers of inverted T-waves (see Figure 15). Using all the data from the 30 second
intervals, averages were obtained for the following parameters (QRS, QTc, T peak to T
end, Tc, STc) for each group for statistical analysis.
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Echocardiography Methods
ECHOs were done on every mouse studied during the various weeks in vivo
studies were conducted. The methods used to conduct the measurements and analyze
them were exactly the same as those used in the study by Horenziak. However they were
unable to be used due system recording and copying failures.
Statistical Methods
All data was analyzed using JMP® 8, and checked for normality, outliers, and
equal variances prior to ANOVA and t testing. After the data was checked for normality,
outliers, and equal variances the appropriate statistical test was conducted to determine if
significance existed. All comparisons were checked for significance using a α of 0.05.
All graphs show the standard error unless otherwise noted.
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IV. Results
Results of Body and Tissue weights Analysis
Mouse body weights showed marked differences based on whether they were
exposed to sarin or not. Sarin mice were approximately two grams lighter than those not
exposed throughout the study with a significance at an α of 0.05 (see Figure 16).

Figure 16. Body Weight Measurements from the Atropine Study

Another noticeable trend was after the atropine/2PAMCL injection of the control mice
there was weight loss of around one gram in the group (although not significantly less).
There was no loss of weight in the control mice over the same time period. The
control+atropine mice did recover the lost weight by week seven when compared to the
control mice (see Figure 17). There was also a slight loss of weight in the sarin treated
mice after the second injection; however, it was not significant at the 0.05 level. There
was also no difference in body weight in the first four days between the sarin and
sarin+atropine groups. However, by week seven the sarin+atropine mice showed much
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lower body weight than the sarin group, but it was not significant at the 0.05 level (p =
0.054), (see Figure 18).

Figure 17. Comparison of Control and
Control+Atropine/2PAMCL groups Body Weight

Figure 18. Comparison of Sarin and
Sarin+Atropine/2PAMCL groups Body Weights

In the β adrenergic drug therapy study there was a significant difference between
the isoproterenol and the propranolol treatment group during week nine at the 0.05 level
(see Figure 19). Body weights of the week 10 control mice from the Horenziak were
taken and compared to the week nine and 11 body weights of the β adrenergic drug
therapy study (the mice from the Horenziak study were treated in the same manner as the
mice in this study). The control body weights averaged 38.22g ± 1.25g the continued
lower body weight of sarin treated mice to control mice was still observed at both weeks
nine and 11. At the time of sacrifice the sarin+propranolol group’s body weight was
found to be significantly lower than both the other β adrenergic drug therapy groups (p =
0.0001 (iso) and 0.002 (saline), see Table 3, Appendix A).
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Figure 19. β adrenergic drug therapy study Body Weight Comparisons

Heart weights were normalized to mice body weights (HW/BW) and analyzed to
compare overall heart size. The mice in the atropine study showed no significance
between any of the treatment groups versus the control group (α = 0.05, see Table 2).

Table 2. Atropine Study HW/BW Ratios

Average
SEM

Atropine Study HW/BW Ratio
Control
Sarin
Conrol+A Sarin+A
4.75
4.98
5.08
5.13
0.11
0.20
0.19
0.16

Additionally, there was no significance between any of the treatment groups (F prob =
0.8546). The overall trend in the atropine study mice, while not significant, shows a
slight increase in the ratio of HW/BW from control, sarin, control+atropine/2PAMCL,
sarin+atropine/2PAMCL (see Figure 20). The β adrenergic drug therapy study mice
groups had no control group from this study, so the control group (sacrificed at week 10)
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from the study done by Horenziak was used for comparison. Each treatment group
(saline, isoproterenol, propranolol) showed significantly higher ratios versus the control
group at the 0.05 level (p = 0.0334, 0.0014, 0.0078). There was also a significant
difference between the isoproterenol group (5.58 ± .32) and the saline and propranolol
groups (4.52 ± 0.04, 4.70 ± 0.07), (F prob = 0.0018). Additionally, there was no
noticeable affect by the propranolol treated mice compared to the saline treated mice (p =
0.75).

Figure 20. HW/BW Ratios for the Atropine and β Adrenergic Drug Treatment Studies

Results of Cell Size Analysis
The atropine study group showed significant increases in cell size of all
treatments versus the control at the 0.05 level (see Figure 21). Additionally an one-way
ANOVA between the treatment groups showed a significant difference between sarin
only and those treated with atropine/2PAMCL (F prob = 0.0014).
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Figure 21. Atropine Study Cardio Myocyte Size Results

When compared to the Atropine study the β adrenergic drug therapy study shows a trend
to larger cell size. Due to slight differences between analysis techniques in this study and
Horenziak’s, his week 10 H&E control data could not be compared with data from the β
adrenergic drug therapy study. The β adrenergic drug therapy study showed a decrease in
the cell size of the isoproterenol (339µm2 ± 12 µm2) treated mice versus the saline
(383µm2 ± 5 µm2) treated mice (p = 0.0296). Additionally, there was a trend showing
reduced cell size in the propranolol group versus the saline treated group (see Figure 22).
Examples of the cell sizes can be seen in the pictures in Appendix C.
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Figure 22. β Adrenergic Drug Therapy Cardio Myocyte Size

Results of ECG Analysis
The results of the ECG analysis are twofold; first, the actual changes in QTc, STc,
and Tc intervals pre and post dobutamine stress testing and second, the changes in Twave morphology pre and post dobutamine stress testing. Of the two, the T-wave
morphology provides the most meaningful indicators of the possible remodeling that was
occurring and the extent. The week three ECG recordings showed a trend for larger
percent differences in the sarin treated mice versus control mice for QTc and Tc intervals,
however only the QTc difference was significantly different (p = 0.049). There was also
a noticeable decrease in the STc segment in both groups (see Figure 23).
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Figure 23. ECG Results from Week 3

At week seven the sarin and control+atropine/2PAMCL groups showed a decrease in the
percent differences of the QTc intervals versus the control (ChiSq = 0.005 and 0.045).
The STc segments for the treatment groups were lower than the control groups, however;
they were not statistically significant at the 0.05 level. Additionally, the percent
difference of the Tc segment from the control group was larger than all three treatment
groups, significantly so, compared to the sarin and sarin+atropine/2PAMCL groups
(ChiSq = 0.049 and 0.022), (see Figure 24).

Figure 24. ECG Results from Week 7
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At week nine all mice were essentially sarin treated mice as defined by study protocol.
After dobutamine stress testing large numbers of mice began showing signs of T-wave
inversion. All mice that showed T-wave inversion had larger percent differences for
QTc, STc, and Tc, compared to the STc depressed mice (p = 0.07, 0.10, 0.07
respectively), (see Figure 25).

Figure 25. Comparison Between Mice with and without T-Wave Inversion at Week 9

The ECG results for week 11 (after two weeks of drug treatment) showed significance in
the QTc segment difference at the 0.05 level for all groups (saline, isoproterenol,
propranolol) versus the control (ChiSq = 0.025, 0.004, and 0.029). There was no
difference found between the STc segment percent differences, however, the
isoproterenol and propranolol groups did show significantly lower values versus the
control for the Tc segment (ChiSq = 0.004 and 0.01), (see Figure 26).
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Figure 26. ECG Results from Week 11

Additional analysis of the T-waves on the ECG readouts showed increased levels of Twave depression and inversion in the sarin exposed mice versus the controls in weeks
three and seven. Comparison of week nine and week 11 T-waves showed the effects of
the drug treatments on the mice. The isoproterenol treated mice showed increased heart
stress, pre-dobutamine, while the propranolol treated mice showed no T-wave inversions
after treatment compared to four out of seven mice at week seven (Appendix B has
examples of T-wave morphology in the ECG readings).
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Figure 27. Comparison of T-Wave Variations at Week 3, 7, 9, and 11

Comparison of the week seven and nine sarin groups shows a continued increase in the
morphology of the T-wave post dobutamine injection with little to no change in pre
dobutamine indicators for sarin treated mice (see Figure 28).

Figure 28. Weeks 7 and 9 T-wave Comparisons

Results of BNP Analysis
BNP staining was done at the end of this study. Initial qualitative examination of
the slides showed increases in BNP levels for sarin and atropine/2PAMCL treated mice
which was later confirmed by analysis of the atropine study group (see Figure 29).
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Figure 29. Examples of BNP perfusion in Control, Control+Atropine/2PAMCL, and Sarin+Atropine/2PAMCL
mice ventricles

There were also possible increases in the week 11 mice BNP levels in the sarin+saline
mice and decreases in the isoproterenol and propranolol treated mice versus the control.
The ratio of BNP to total cell area showed significant differences between the
atropine/2PAMCL treated mice (both control and sarin) versus the control (p = 0.028 and
0.0001 respectively), (see Figure 30).

Figure 30. Results of BNP Analysis from the Atropine Study
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There was even a significant difference between the sarin+atropine/2PAMCL and sarin
treated mice (p = .0001). Comparison of BNP levels in the β adrenergic drug treatment
groups were not significant at the 0.05 level (see figure 31).

β Adernergic Drug Treatment
BNP to Cell Area Ratios
0.35
0.3

Wk10 Control

0.25

Sarin+Saline
Sarin+Isoproterenol

0.2

Sarin+Propranolol
0.15
BNP/Cell Area Ratio
Figure 31. Results of BNP Analysis form the Β adrenergic drug therapy study
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IV. Discussion
Introduction
Results of previous studies have shown that a single exposure to asymptomatic
levels of sarin nerve agent can lead cardiac remodeling. This study looked to determine
whether the standard treatment for nerve agent exposure, (atropine/2PAMCL) could
protect the heart from long term remodeling. Additionally sarin exposed mice were
treated with β receptor agonists and antagonists to look at their effects on cardiac
performance and morphology.
Atropine/2PAMCL Study Discussion
Change in body weight can be an indicator of any number of harmful conditions.
There was a significant difference in body weights between the control and sarin exposed
mice (28.17g ± .33 vs. 25.78g ± .34). The atropine/2PAMCL treated groups showed
decreases of approximately 1g in body weight post treatment (Table 4, Appendix A). By
week three the two different sarin groups had both regained their weight. This effect of
weight loss after sarin exposure has been well documented (Bide & Risk, 2004; Grauer,
et al., 2008; Shih, et al., 2006). All groups showed a continued increase in body weight
into week seven. Due to the steady (there was no sudden increase in body weight
noticed) weight gain over time after the initial exposures and treatments, it is not believed
to be a factor in the noticed cardiac performance differences between groups.
Heart weight is an important indicator of overall performance and heart health.
There was a noticeable upward trend in HW/BW ratios from control, sarin,
control+atropine/2PAMCL, sarin+atropine/2PAMCL (Table 3, Appendix A), which
cannot be explained by cholinergic insult. While noticeable, the upward lacked
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significance at the 0.05 level due to large variances which were caused by the small
sample size. All physiological data collected from the sarin group up to week seven were
consistent with previous findings which show induced long term hypertrophy in mice
after sarin exposure. The physiological results showed that the atropine/2PAMCL
treatment had more profound markers for hypertrophy than the sarin data, which was not
expected.
Along with slightly larger HW/BW ratios the cell size analysis of the
atropine/2PAMCL groups also showed that the cardio myocytes of the two groups are
significantly larger than both the control and sarin groups at week seven (Table 3,
Appendix A). This increase in cell size is also an indicator of hypertrophy (Takeda, et al.
2010, Harada, et al. 1997). Analysis of BNP levels in heart tissue is used as an indicator
of cardiac insult and possible damage. The results of the BNP analysis also point to
greater cardiac insult due to atropine/2PAMCL treatment. The higher levels of BNP in
both groups treated with atropine/2PAMCL (34.2% ± 5.6 and 24.4% ± 2.1) versus the
control (14.7% ± 2.4) support this. Of interest is the difference even between control and
sarin atropine/2PAMCL groups which suggests a possible additive affect of the two
agents.
ECG’s are used to identify changes in the electrical impulse propagation in the
heart. Anomalies in the recordings allow for in vivo observation of cardiac performance.
The ECG data in the atropine study shows markers which are indicative of hypertrophy in
both sarin and atropine/2PAMCL treated mice. The atropine/2PAMCL groups showed
an increase in QTc intervals which is a sign of possible hypertrophy (Abraham, et al.
2001). The Tc segment changes were also noted which is due to the presence of ST
46

depression and inverted T-waves after dobutamine stressing. Two-thirds of the
atropine/2PAMCL nearly two-thirds of the sarin treated mice showed ST point
depression or T-wave inversion, which are both signs of ischemia in mice (Lambiase, et
al. 2003, Chu, et al. 2001, Stoller, et al. 2007, Tomai, et al. 1999). Ischemia has also
been shown to be an indicator of hypertrophy due to inability of the coronary circulatory
system to adequately supply blood to hypertrophic cardiac muscle tissue (Smits and
Smits 2004). These results of mice treated with atropine/2PAMCL might be the result of
long term damage to the muscarinic receptors caused by the atropine treatment, which
caused an increase in heart rate at the time of treatment (possibly stressing the heart).
β Adrenergic Drug Therapy Study Discussion
Treatment of various heart conditions (including hypertrophy) involve the use of
drugs which either stimulate or block the normal function of β adrenergic receptors. By
looking at the effects of these drugs on sarin exposed mice insights into therapeutic
treatments can be gained. The mice in the β adrenergic drug therapy study were treated
with a 0.4LD50 dose of sarin and experienced similar changes in weight loss and gain as
the sarin mice in the atropine study. After the administration of the drug treatments at
week nine all groups showed increases in body weight by week 11, however overall body
weights were still significantly lower than the week 10 control mice, these results are
consistent with the previous studies results (Horenziak 2010).
After normalization of the heart weights from week 11, using the body weight,
and comparing them to the week 10 control mice, all treatment groups showed
significantly larger HW/BW ratios than the control mice (see Table 3, Appendix A). The
isoproterenol group also showed significantly larger HW/BW ratios than either treatment
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group (see Table 3, Appendix A), this was expected as long term treatment with
isoproterenol is known to induce hypertrophy (Ramos, et al. 2003, Hoffman 2001). The
propranolol group showed significant change versus the control, but not against the sarin
group. This lack of hypertrophic reversal is most likely due to the low level of
propranolol used (20mg/kg), a study in rats showed hypertrophic reversal at doses of 40
and 80 mg/kg body weight, but not at 10mg/kg (Marano, et al. 2002). Cell size analysis
showed lower cell size in the isoproterenol and propranolol groups versus the saline
treated mice. Only the isoproterenol group showed statistical significance (see Table 5,
Appendix A). The smaller size of the isoproterenol group is most likely due to increased
cell division of the cardio myocytes (Nadal-Ginard, et al. 2003).; This assumption was
unable to be confirmed. The decrease in the propranolol is likely the beginning of
possible hypertrophic reversal but again was unable to be verified.
The BNP analysis showed similar results as the cell size analysis. The BNP
levels were lower in both the isoproterenol and propranolol versus the saline group (but
for different reasons). The isoproterenol results are most likely due to the increase in
cardio myocytes which would result in a decrease in cardiac stress and thus a decrease in
BNP levels. The decrease in propranolol BNP levels is likely due to the antihypertrophic effects of the drug which leads to lower cardiac stress and lower BNP
levels.
At week nine there were noticeable differences between mice which underwent Twave inversion and those which showed ST depression post dobutamine stressing. While
none of the differences (QTc, STc, Tc) were significant at the 0.05 level (p = 0.07, 0.11,
0.07), the mix between the two affected the statistical comparisons of the segment
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intervals. The week 11 data for the saline treated group showed similar results as the
weeks seven and nine sarin mice, which are all indicative of hypertrophy (see Table 6,
Appendix 4). Looking at the mice T-waves pre and post dobutamine stressing shows the
lack of anomalies pre dobutamine stress testing, and their presence after dobutamine
stressing. The isoproterenol treated mice showed almost exclusive T-wave inversion pre
and post dobutamine stressing which indicates that the heart was already stressed (which
is expected after treatment with isoproterenol). This initial stressed state of the hearts
resulted in no change of the QTc interval and reversed trends in STc and Tc differences
after the injection of dobutamine. The results show that after treatment with
isoproterenol the mice lacked any cardiac reserve and failed to respond to the dobutamine
stimulus. The propranolol treated mice showed no T-wave inversion (it was present at
week nine), but instead showed complete ST depression after dobutamine stress testing.
ST depression is a sign of remodeling in heart tissue and may indicate the beginnings of
hypertrophic reversal from the propranolol treatment. There was no difference in the Tc
interval in propranolol treated mice and a small increase in the QTc interval, but they
showed an increase in the STc interval.
Limitations of the Study
Due to the inability to conduct ECHO recordings on all mice during the data
collection weeks, not all mice underwent dobutamine stress testing in weeks three and
seven. This resulted in a lack of complete ECG and body weight data for these weeks,
preventing meaningful timeline analysis using these parameters. This incomplete testing
of all groups at weeks three and seven also lowered the overall n for each group, thus
lowering the ANOVA statistical power. Another limitation of this study is the lack of
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baseline data for the ECG recordings for each mouse before sarin exposure. Obtaining an
ECG baseline, would have allowed for more in-depth analysis on the timeline of cardiac
changes.
Additional limitations of the studies were that there was only one treatment (dose)
level of atropine/2PAMCL and propranolol in the studies. Without being able to test
multiple dose levels it was not possible to determine if their effects could be beneficial at
different dose levels to either prevent or treat hypertrophy in cardio myocytes after
exposure to sarin at asymptomatic doses.
This study looked at BNP levels in the cardiac tissue post sacrifice. There are
assay kits which measure BNP levels in blood plasma in mice. Utilizing these kits pre
and post sarin exposure would have allowed for a more complete analysis of the onset of
cardiac remodeling.
Future Work
To more accurately determine if the atropine/2PAMCL treatment could be
beneficial in treating possible low dose exposure to sarin, a range of treatment doses
should be tested. The same study should be done with propranolol to determine if larger
doses per kg of body mass would result in reversal of the hypertrophic effects of sarin.
Further studies should also continue to look at the mechanism of action of sarin on the
cardiac system. Additional studies of possible treatment protocols should also be
explored to see if there is one that can effectively prevent or treat the cardiac remodeling
caused by low dose sarin exposure. Additionally, the use of BNP levels in the blood
should be analyzed to look at levels over time to see if they change over time and
correspond to other markers of cardiac remodeling.
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Conclusion
All data obtained during the two studies reinforced the findings by Horenziak,
that acute low dose sarin exposure causes hypertrophy in the hearts of mice. The
standard antidote treatment dose of atropine/2PAMCL (10 and 25 mg/kg) in rodents is
not effective in preventing hypertrophy in cardiac tissue of mice, in fact, the data
collected on the mice treated in this manner showed stronger markers of hypertrophy than
the sarin treated mice. The increased stress on the heart from isoproterenol and increased
cardiac load of sarin mice after dobutamine injection indicate that the low dose sarin
exposure does not damage the β1 adrenoreceptor cascade. This suggests that it would be
possible to treat the hypertrophic effects caused by sarin with propranolol possibly
reversing the hypertrophy if proper dose levels can be determined.
The ECG recordings of these studies continued to show the insidious nature of
low dose sarin exposure by appearing normal prior to dobutamine stress testing. These
results are of extreme interest to the military community for several reasons. First, most
early warning equipment employed by the military are designed and employed to detect
levels of CWA that pose a direct threat to life or limb. These levels are higher than
symptomatic doses, thus, they would not be able to detect nerve agents at the
asymptomatic dose levels used in this experiment. Second, based on the normal cardiac
output that is present at a non-stressed state, personnel exposed to asymptomatic levels
would show no issues during normal activities, such garrison or non-field operations.
However, this would quickly change during periods of high cardiac output, i.e., physical
fitness training, deployment operations, and field operations, which, could affect heart
performance or result in heart failure of the Soldier. Third, current post deployment
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physicals occur far before these symptoms would present themselves and annual
physicals do not include a heart stress test unless there are extenuating circumstances. It
is therefore extremely important that any possible (no matter how minor) exposure to
nerve agents be reported and be included in Soldiers’ medical records to ensure proper
medical care in the future. These physical concerns of heart performance, holes in the
current medical screening process, and detection limitations of CWA’s demonstrate the
need for further examination of low dose toxicological effects of sarin.
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Appendix A: Data Tables

Table 3. HW/BW Ratio Data

Average
SEM

Atropine Study HW/BW Ratio
Control
Sarin
Conrol+A Sarin+A
4.75
4.98
5.08
5.13
0.11
0.20
0.19
0.16

Average
SEM

β adrenergic drug therapy HW/BW Ratio
Control*
Sarin
Iso
Prop
4.02
4.52
5.58
4.70
0.25
0.04
0.32
0.07
* Indicates data used from a separate study

Table 4. Body Weight Data

control
sarin
control+A
sarin+A

Average
SEM
Average
SEM
Average
SEM
Average
SEM

Sarin +
Average
saline
SEM
Sarin +
Average
isoprterenol
SEM
Sarin +
Average
propranolol
SEM

3/4/10
28.17
0.33
25.78
0.34
28.32
0.29
25.37
0.34

3/4/10
26.24
0.30
25.70
0.35
24.76
0.62

Atropine Study Groups Body Weights
3/5/10
3/6/10
3/8/10 week 3 week 7
27.96
27.92
27.82
28.88
31.05
0.32
0.35
0.22
0.54
0.96
25.75
25.31
25.42
26.34
30.68
0.36
0.31
0.33
0.46
0.75
28.03
26.92
26.96 No Data
31.00
0.26
0.49
0.87
No Data
0.65
25.56
25.16
25.25 No Data
27.17
0.35
0.45
0.34
No Data
0.72

3/5/10
25.99
0.21
24.91
0.44
24.64
0.75

Sacrifice
31.36
0.83
29.25
0.45
31.68
0.54
27.86
0.53

Drug Treatment Study Groups Body Weights
3/6/10
3/8/10 week 7 week 9 week 11 Sacrifice
25.57
25.79
29.02
29.20
31.61
31.43
0.25
0.27
0.44
0.56
0.53
0.43
24.65
24.34
28.38
29.83
32.28
32.83
0.67
0.91
0.41
0.89
0.45
0.41
24.17
24.85
28.75
28.56
29.70
28.59
0.78
0.44
0.95
1.07
0.69
0.61
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Appendix A: Data Tables

Table 5. Cardio Myocyte Cell Size Data

Average
SEM

Atropine Study Groups Cell Sizes (µm²)
Control Sarin Control+Atropine/2PAMCL Sarin+Atropine/2PAMCL
221
280
321
324
15
10
9
6

β adrenergic drug therapy Cell Sizes (µm²)
Sarin + Saline Sarin + Isoproterenol Sarin + Propranolol
Average
383
339
360
SEM
5
12
14

Table 6. T-Wave Comparison Data

normal
ST depressed
T wave inversion

normal
ST depressed
T wave inversion

normal
ST depressed
T wave inversion

Week 3 Atropine Study T-Wave Types
Control
Sarin
pre d
post d
pre d
post D
7
4
6
0
0
2
0
5
1
2
1
2

Control
pre d
post d
6
3
0
1
0
2

Week 7 Atropine Study T-Wave Types
Control+Atropine
Sarin
pre d
post D
pre d
post d
2
1
16
7
0
1
1
8
3
3
2
4

Sarin+Saline
pre d
post d
6
1
0
2
1
4

Wave Type
normal
ST depressed
T wave inversion

Sarin+Atropine
pre d
post d
5
3
1
2
1
2

Week 9 Drug Treatment Study T-Wave Types
Sarin+Isoproterenol Sarin+Propranolol
Combined
pre d
post D
pre d
post d
pre d
post d
7
1
4
0
17
2
0
4
1
3
1
9
0
2
2
4
3
10

Week 11 Drug Treatment Study T-Wave Types
Sarin+Saline
Sarin+Isoproterenol Sarin+Propranolol
pre d
post d
pre d
post D
pre d
post d
5
2
0
0
2
0
0
2
1
1
3
5
1
2
5
5
0
0

54

Appendix A: Data Tables

Control
Week 3
Sarin
Week 3
Control
Week 7
Sarin
Week 7
Iso+Prop
+Sal
Week 7
Combine
d Sarin
Sarin
Minus T
Control+
Atro
Week 7
Sarin+Atr
o Week 7

Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD

QRS pre
14.88
3.33
15.46
1.69
15.36
1.04
15.93
1.92
14.89
1.30
15.22
1.55
15.27
1.21
14.67
0.85
15.83
1.38

QRS post
14.40
2.80
15.14
1.95
15.59
1.53
15.93
1.98
14.97
1.08
15.27
1.44
15.28
1.08
14.76
0.64
15.80
1.39

Tpe pre
24.99
6.12
24.73
5.76
21.43
5.91
27.84
8.43
25.74
6.72
26.41
7.13
25.80
5.51
30.21
1.98
26.23
11.07

Table 7. Atropine Study ECG Data
Tpe post HR pre HR post QTc pre QTc post STc2 pre STc2 post Tc2 pre Tc2 post % diff QTc % diff STc2 % diff Tc2
29.46 454.26 548.90 51.14 55.41 17.57 14.81 21.27 27.90
0.09
-0.11
0.36
7.17 49.28 53.36 4.44
6.04
5.24
3.75
4.90
6.04
0.16
0.30
0.37
32.39 395.79 537.25 47.17 58.55 14.76 13.59 19.84 30.61
0.25
-0.08
0.59
3.61 54.36 40.71 4.91
5.34
3.27
5.66
3.73
3.46
0.11
0.37
0.37
28.13 446.68 577.46 44.36 57.30 12.81 14.59 18.29 27.41
0.31
0.14
0.56
7.19 52.25 47.02 4.71
4.28
1.20
6.38
4.24
6.28
0.21
0.52
0.47
29.72 492.39 550.80 51.35 54.38 11.62 10.65 25.33 28.49
0.06
0.00
0.18
3.82 63.07 46.27 5.41
7.14
6.07
6.61
8.48
4.19
0.10
0.52
0.21
26.92 460.61 590.66 49.35 54.08 13.75 12.61 22.58 26.63
0.11
-0.10
0.28
4.99 42.38 54.10 5.67
2.87
2.86
4.99
6.10
4.81
0.17
0.29
0.54
28.06 470.64 578.07 49.98 54.17 13.08 11.99 23.45 27.21
0.10
-0.07
0.25
4.73 50.32 53.93 5.52
4.43
4.09
5.44
6.82
4.59
0.15
0.37
0.46
26.54 464.84 580.18 50.05 53.67 13.96 12.88 22.68 25.78
0.07
-0.09
0.17
3.54 50.32 59.98 3.22
4.40
3.98
5.40
5.14
3.33
0.09
0.26
0.18
32.01 414.93 540.88 52.00 57.67 14.74 13.33 25.09 30.38
0.11
-0.04
0.21
4.72 46.73 69.28 3.34
2.44
2.28
7.05
2.19
5.43
0.10
0.51
0.17
25.13 490.02 588.78 49.40 53.18 11.87 13.04 23.30 24.53
0.09
0.07
0.09
7.15 69.49 70.79 11.30 9.43
5.28
6.70
8.70
5.62
0.16
0.38
0.15
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% diff HR
0.22
0.14
0.38
0.20
0.31
0.17
0.13
0.09
0.29
0.14
0.24
0.14
0.26
0.14
0.30
0.06
0.21
0.14
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Table 8. β adrenergic drug therapy study ECG Data

Sarin+Sal
ine Week
9
Sarin+Iso
Week 9
Sarin+Pro
p Week 9
Combine
d Sarin
Week
Sarin9
Minus T
Inverw/
Sarin
T Inver
Week
Sarin 9
Week 11
Sarin+Iso
Week 11
Sarin+Pro
p Week
11 10
Week
Control *

Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD
Average
STD

QRS pre
15.83
1.38
16.25
1.48
16.06
2.46
16.05
1.75
15.56
1.61
16.58
1.83
17.48
0.83
16.77
1.65
16.75
3.57
16.49
2.42

QRS post
16.01
2.07
15.69
2.08
15.87
2.55
15.86
2.13
15.26
1.77
16.51
2.39
18.76
1.73
16.87
1.74
16.32
3.84
17.33
2.62

Tpe pre
29.76
4.56
20.39
6.09
27.74
10.29
25.97
8.13
26.87
9.21
24.97
7.11
28.15
2.09
33.96
8.04
48.08
12.12
21.19
4.10

Tpe post
31.25
9.03
31.34
9.51
31.71
7.81
31.43
8.36
28.07
6.20
35.13
9.14
29.76
7.05
29.80
9.48
40.81
5.65
27.17
4.47

HR pre
404.68
30.36
458.99
52.70
468.32
45.64
444.00
50.61
463.46
43.70
422.59
50.97
430.60
35.95
555.60
64.66
384.05
54.16
395.22
31.74

HR post
589.32
28.99
636.80
41.80
613.58
30.14
613.23
37.99
626.07
35.90
599.11
36.78
541.34
33.55
557.08
62.12
503.28
46.47
553.55
242.91

QTc pre
51.63
4.90
46.87
5.40
53.76
7.36
50.75
6.40
51.64
5.50
49.77
7.44
53.89
4.41
62.14
1.72
63.26
9.71
4.42
0.53

QTc post STc2 pre STc2 post Tc2 pre Tc2 post % diff QTc % diff STc2 % diff Tc2 % diff HR
59.67 14.24
12.87
24.41 30.94 0.16
0.02
0.28 0.46
6.16
3.29
6.64
3.79
8.84
0.15
0.73
0.39 0.11
57.50 14.96
9.19
17.71 32.21 0.24
-0.37
0.96 0.40
5.00
3.28
7.50
5.08
9.59
0.17
0.55
0.83 0.18
58.04 15.19
10.00
24.34 32.01 0.10
-0.33
0.48 0.32
9.02
4.27
7.32
8.44
7.69
0.25
0.49
0.60 0.12
58.40 14.80
10.69
22.15 31.72 0.17
-0.22
0.58 0.39
6.64
3.48
6.99
6.62
8.32
0.19
0.60
0.67 0.15
55.80 14.62
11.65
21.38 28.59 0.09
-0.16
0.33 0.36
7.77
2.95
5.49
9.75
5.90
0.14
0.43
0.43 0.14
61.27 14.99
9.63
18.97 35.17 0.26
-0.29
0.84 0.43
3.69
4.15
8.52
8.33
9.48
0.20
0.76
0.79 0.15
57.40 15.32
11.26
23.78 28.36 0.09
-0.16
0.24 0.27
7.44
4.78
3.43
1.04
7.10
0.16
0.31
0.35 0.08
62.05 13.68
17.48
32.29 28.29 0.00
0.28
-0.14 0.00
2.03
3.78
5.54
6.05
7.93
0.02
0.17
0.13 0.02
66.09 11.89
14.12
38.06 37.16 0.06
0.19
0.00 0.32
4.98
3.51
4.45
8.15
3.60
0.10
0.15
0.15 0.16
5.66
13.78
14.19
17.11 25.84 0.30
0.34
0.47 0.40
0.46
4.83
3.34
3.07
3.97
0.17
0.22
0.28 0.25
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Appendix B: ECG Pre and Post Dobutamine Recordings

Typical End of S
in a Mouse

No ST Depression
STC
STC

TC

TC

Figure 32. Control Mouse ECG Trace Before
Dobutamine Injection
The end of S rises above the iso-electric point and the Twave tail falls below the iso-electric point before
returning (marking the iso-electric relaxation time). Note:
as depicted TC is not corrected by the (RR/100)1/2.

Figure 33. Control Mouse ECG Trace After
Dobutamine Injection
The end of S rises above the iso-electric point. The STC
segment and TC segments do not change markedly.

No ST
Depression

ST Depression

STC

STC

TC

TC

Figure 34. Sarin Mouse ECG Trace Before
Dobutamine Injection
The end of S rises above the iso-electric point slightly less
than the controls (but not markedly).
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Figure 35. Sarin Mouse ECG Trace After
Dobutamine Injection Showing ST Depression
The end of S does not rise to the iso-electric point. The
STC segment is slightly shortened when compared to the
controls and TC segment is significantly lengthened.

Appendix B: ECG Pre and Post Dobutamine Recordings

ST Slightly
Depressed
for a Mouse

STC

Severe ST
Depression

TC

STC

TC

Figure 36. Sarin Mouse ECG Trace Before
Dobutamine Injection
The ST is slightly depressed. The T-wave tail falls below
the iso-electric point before returning.

Figure 37. Sarin Mouse ECG Trace After
Dobutamine Injection Showing Severe ST Depression
The end of S does not rise to the iso-electric point. The
STC segment is significantly shortened when compared to
the controls and TC segment is significantly lengthened.

Figure 38. Isoproterenol Treated Mouse ECG
Trace Before Dobutamine Injection
The T-wave is already inverted and ends at the start of
the P-wave

Figure 39. Isoproterenol Treated Mouse ECG
Trace After Dobutamine Injection
There was no change in the T-wave even after
dobutamine injection
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Appendix C:
H&E Stained Slide Picture Examples Used for Cell Size Analysis

Figure 40. Photos of Each Treatment Group from the Atropine Study
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Appendix C:
H&E Stained Slide Picture Examples Used for Cell Size Analysis

Figure 41. Photos From the β Adrenergic Drug Treatment Study
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Appendix D: Masson’s Trichrome Photos

Figure 42. Masson's Trichrome Photos from Atropine Study
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Appendix D: Masson’s Trichrome Photos

Figure 43. Masson's Trichrome Photos from β Adrenergic Drug Treatment Study
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